Clinical trials: Sildenafil
- Drug or intervention Sildenafil
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)
This protocol is for subjects with pulmonary arterial hypertension and is the first of 3 studies forming the Sitaxsentan efficacy and safety trial with Randomized Prospective Assessment of Adding Sildenafil (SR-PAAS) program.
- Trial name
- NCT00795639
- Testing
- Sitaxsentan
- Where
- 85 sites in United States, Argentina and 22 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
Pulmonary Hypertension
The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH
Determination of the effects of sildenafil citrate and epoprostenol when used in combination in patients with pulmonary arterial hypertension
- Trial name
- NCT00159861
- Testing
- Sildenafil citrate
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
An Open Label Access Study For Subjects Who Completed A1481156
The purpose of this study is to provide sildenafil therapy to subjects who have completed the A1481156 study for the treatment of Pulmonary Arterial Hypertension (PAH) in India and are judged by the Investigator to derive…
- Trial name
- NCT01582438
- Testing
- Access program - sildenafil citrate, Viagra, Revatio
- Where
- India
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
PPHN, Persistent Pulmonary Hypertension of the Newborn
Study To Investigate Safety And Efficacy Of Sildenafil In The Newborns With Persistent Pulmonary Hypertension (PPHN)
Sildenafil is efficacious in newborns with persistent pulmonary hypertension and its use will reduce the need for inhaled nitric oxide.
- Conditions
- PPHN, Persistent Pulmonary Hypertension of the Newborn, Hypoxic Respiratory Failure
- Trial name
- NCT01069861
- Testing
- sildanefil
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Hypertension, Persistent, of the Newborn
A Non-Interventional Follow Up Study For Subjects Who Received Sildenafil for Persistent Pulmonary Hypertension of the Newborn (PPHN)
This single center study will monitor the developmental progress of PPHN patients who received iv sildenafil in study A1481276. Two visits will be conducted, at 12 and 24 months following the end of study drug infusion.
- Trial name
- NCT01801982
- Testing
- non-interventional
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Persistent Fetal Circulation Syndrome
Sildenofil in Persistent Pulmonary Hypertension in Newborns
This study hopes to evaluate the effectiveness of early combined use of Sildenafil and nitric oxide (iNO) in newborns with Persistent pulmonary hypertension (PPHN) and or hypoxemic respiratory failure and assess whether this…
- Trial name
- Sildeno (NCT01558466)
- Testing
- Sildenafil, diluent
- Where
- Qatar
- Volunteers
- 100 people
- Sponsor
- Hamad Medical Corporation
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary arterial hypertension (PAH)…
- Trial name
- NCT00796510
- Testing
- Sitaxsentan, Sitaxsentan and Sildenafil
- Where
- 3 sites in United States, Romania and 1 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Pulmonary Hypertension
The "VISION" Trial: Ventavis Inhalation With Sildenafil to Improve and Optimize Pulmonary Arterial Hypertension
The purpose of this multi-center international trial is to evaluate the safety and effectiveness of adding iloprost or placebo (an inactive substance that contains no active study drug) to sildenafil therapy for pulmonary…
- Trial name
- VISION (NCT00302211)
- Testing
- Inhaled Iloprost (5 μg), Sildenafil, Bosentan
- Volunteers
- 67 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Hypertension, Pulmonary
Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening disease. In many patients, the course of PAH is a steady deterioration and reduced life expectancy.
- Trial name
- NCT01642407
- Testing
- Sildenafil
- Where
- 5 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil
The purpose of this study is to provide Sildenafil therapy for subjects who completed A1481156 study and are judged by the investigator to derive clinical benefit from continued treatment with Sildenafil, prior to reimbursement…
- Trial name
- NCT01897740
- Testing
- sildenafil
- Where
- Russia
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension
Special Investigation For Long-Term Use Of Sildenafil (Regulatory Post Marketing Commitment Plan)
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00666198
- Testing
- SILDENAFIL
- Volunteers
- 3,337 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)
COMPASS-2 is a Phase 4, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first confirmed morbidity/mortality event in patients with symptomatic PAH…
- Trial name
- Compass-2 (NCT00303459)
- Testing
- bosentan
- Volunteers
- 334 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension, Children
A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.
This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years.
- Trial name
- NCT00159913
- Testing
- Sildenafil citrate
- Where
- 41 sites in United States, Brazil and 15 more
- Volunteers
- 235 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.
- Trial name
- NCT00159874
- Testing
- Sildenafil citrate
- Where
- 39 sites in United States, Brazil and 13 more
- Volunteers
- 234 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Persistent Pulmonary Hypertension of the Newborn
IV Sildenafil Persistent Pulmonary Hypertension Of The Newborn
To determine the efficacy of iv sildenafil in term and near term infants with PPHN (persistent pulmonary hypertension of the newborn), by measuring the need for inhaled nitric oxide (iNO) or extracorporeal membrane oxygenation…
- Trial name
- NCT01360671
- Testing
- Sildenafil
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects…
- Trial name
- ATHENA-1 (NCT00617305)
- Testing
- Ambrisentan, Sildenafil, Tadalafil
- Where
- 30 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Pulmonary Hypertension, Familial Persistent, of the Newborn
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
This study will evaluate whether IV sildenafil can reduce the time on inhaled nitric oxide treatment and reduce the failure rate of available treatments for persistent pulmonary hypertension of the newborn.
- Trial name
- NCT01720524
- Testing
- iv sildenafil
- Where
- 42 sites in United States, Belgium and 10 more
- Volunteers
- 59 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Combination Therapy in Pulmonary Arterial Hypertension
An open label, non-comparative study design is appropriate for this Phase 4 study designed to assess whether a core therapy of bosentan, either as monotherapy or with the addition of sildenafil, enables patients with pulmonary…
- Trial name
- COMPASS 3 (NCT00433329)
- Testing
- Bosentan, Sildenafil
- Volunteers
- 100 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Revatio Special Investigation for Long-term Use in Pediatric Patients
Secondary data collection study: safety and effectiveness of Revatio in pediatric patients under Japanese medical practice
- Trial name
- NCT03364244
- Testing
- Sildenafil
- Where
- Japan
- Volunteers
- 1,023 people
- Sponsor
- Viatris Pharmaceuticals Japan Inc